Immunic is trading at $7.73, up 5.63%, alongside a biotech-sector rise and broad market rebound; no clear company-specific announcement was identified as the cause of the November 6 move.
- Biotech stocks rose 2.01%; Modernaβs earnings beat and raised outlook were reported as positive sector news.
- Immunic received coverage of its planned Phase 3 progressive-MS trial, but available reporting does not link that news directly to the share-price rise.